Literature DB >> 21156804

Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species.

Asad Jan1, Oskar Adolfsson2, Igor Allaman3, Anna-Lucia Buccarello2, Pierre J Magistretti3, Andrea Pfeifer2, Andreas Muhs2, Hilal A Lashuel4.   

Abstract

The identification of toxic Aβ species and/or the process of their formation is crucial for understanding the mechanism(s) of Aβ neurotoxicity in Alzheimer disease and also for the development of effective diagnostic and therapeutic interventions. To elucidate the structural basis of Aβ toxicity, we developed different procedures to isolate Aβ species of defined size and morphology distribution, and we investigated their toxicity in different cell lines and primary neurons. We observed that crude Aβ42 preparations, containing a monomeric and heterogeneous mixture of Aβ42 oligomers, were more toxic than purified monomeric, protofibrillar fractions, or fibrils. The toxicity of protofibrils was directly linked to their interactions with monomeric Aβ42 and strongly dependent on their ability to convert into amyloid fibrils. Subfractionation of protofibrils diminished their fibrillization and toxicity, whereas reintroduction of monomeric Aβ42 into purified protofibril fractions restored amyloid formation and enhanced their toxicity. Selective removal of monomeric Aβ42 from these preparations, using insulin-degrading enzyme, reversed the toxicity of Aβ42 protofibrils. Together, our findings demonstrate that Aβ42 toxicity is not linked to specific prefibrillar aggregate(s) but rather to the ability of these species to grow and undergo fibril formation, which depends on the presence of monomeric Aβ42. These findings contribute significantly to the understanding of amyloid formation and toxicity in Alzheimer disease, provide novel insight into mechanisms of Aβ protofibril toxicity, and important implications for designing anti-amyloid therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156804      PMCID: PMC3048741          DOI: 10.1074/jbc.M110.172411

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

1.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.

Authors:  C Nilsberth; A Westlind-Danielsson; C B Eckman; M M Condron; K Axelman; C Forsell; C Stenh; J Luthman; D B Teplow; S G Younkin; J Näslund; L Lannfelt
Journal:  Nat Neurosci       Date:  2001-09       Impact factor: 24.884

Review 2.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

3.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

Authors:  R B DeMattos; K R Bales; D J Cummins; J C Dodart; S M Paul; D M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice.

Authors:  M D Kane; W J Lipinski; M J Callahan; F Bian; R A Durham; R D Schwarz; A E Roher; L C Walker
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

5.  Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

Authors:  J McLaurin; R Cecal; M E Kierstead; X Tian; A L Phinney; M Manea; J E French; M H L Lambermon; A A Darabie; M E Brown; C Janus; M A Chishti; P Horne; D Westaway; P E Fraser; H T J Mount; M Przybylski; P St George-Hyslop
Journal:  Nat Med       Date:  2002-10-15       Impact factor: 53.440

6.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

Authors:  D Morgan; D M Diamond; P E Gottschall; K E Ugen; C Dickey; J Hardy; K Duff; P Jantzen; G DiCarlo; D Wilcock; K Connor; J Hatcher; C Hope; M Gordon; G W Arendash
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

7.  Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

Authors:  Jean-Cosme Dodart; Kelly R Bales; Kimberley S Gannon; Stephen J Greene; Ronald B DeMattos; Chantal Mathis; Cynthia A DeLong; Su Wu; Xin Wu; David M Holtzman; Steven M Paul
Journal:  Nat Neurosci       Date:  2002-05       Impact factor: 24.884

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide.

Authors:  Xiaoyan Hu; Scott L Crick; Guojun Bu; Carl Frieden; Rohit V Pappu; Jin-Moo Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-12       Impact factor: 11.205

Review 10.  Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.

Authors:  D M Walsh; I Klyubin; J V Fadeeva; M J Rowan; D J Selkoe
Journal:  Biochem Soc Trans       Date:  2002-08       Impact factor: 5.407

View more
  66 in total

Review 1.  Allosteric function and dysfunction of the prion protein.

Authors:  Rafael Linden; Yraima Cordeiro; Luis Mauricio T R Lima
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

2.  Transthyretin-derived peptides as β-amyloid inhibitors.

Authors:  Patricia Y Cho; Gururaj Joshi; Jeffrey A Johnson; Regina M Murphy
Journal:  ACS Chem Neurosci       Date:  2014-04-09       Impact factor: 4.418

3.  Vildagliptine protects SH-SY5Y human neuron-like cells from Aβ 1-42 induced toxicity, in vitro.

Authors:  Alim Hüseyin Dokumacı; Mukerrem Betul Yerer Aycan
Journal:  Cytotechnology       Date:  2019-04-09       Impact factor: 2.058

Review 4.  Molecular interactions of amyloid nanofibrils with biological aggregation modifiers: implications for cytotoxicity mechanisms and biomaterial design.

Authors:  Durga Dharmadana; Nicholas P Reynolds; Charlotte E Conn; Céline Valéry
Journal:  Interface Focus       Date:  2017-06-16       Impact factor: 3.906

Review 5.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Nature       Date:  2013-09-05       Impact factor: 49.962

6.  The off-rate of monomers dissociating from amyloid-β protofibrils.

Authors:  Clara S R Grüning; Stefan Klinker; Martin Wolff; Mario Schneider; Küpra Toksöz; Antonia N Klein; Luitgard Nagel-Steger; Dieter Willbold; Wolfgang Hoyer
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

7.  Discovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formation.

Authors:  Heiko Kroth; Annalisa Ansaloni; Yvan Varisco; Asad Jan; Nampally Sreenivasachary; Nasrollah Rezaei-Ghaleh; Valérie Giriens; Sophie Lohmann; María Pilar López-Deber; Oskar Adolfsson; Maria Pihlgren; Paolo Paganetti; Wolfgang Froestl; Luitgard Nagel-Steger; Dieter Willbold; Thomas Schrader; Markus Zweckstetter; Andrea Pfeifer; Hilal A Lashuel; Andreas Muhs
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

Review 8.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

9.  Role of aromatic side chains in amyloid β-protein aggregation.

Authors:  Risto Cukalevski; Barry Boland; Birgitta Frohm; Eva Thulin; Dominic Walsh; Sara Linse
Journal:  ACS Chem Neurosci       Date:  2012-09-24       Impact factor: 4.418

Review 10.  Differences between amyloid-β aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease.

Authors:  Samuel A Kotler; Patrick Walsh; Jeffrey R Brender; Ayyalusamy Ramamoorthy
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.